A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Trial Profile

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs DCC 2618 (Primary)
  • Indications Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Solid tumours; Systemic mastocytosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 Updated results from patients with gastrointestinal stromal tumors (GIST) (n = 57) published in a Deciphera Pharmaceuticals media release.
    • 31 Aug 2017 According to a Deciphera Pharmaceuticals media release, updated data will be presented at the 2017 European Society for Medical Clinical Oncology Annual Congress (ESMO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top